Startups
Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in Zytiga-resistant metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit us at https://cardiffoncology.com.
Overview
Location
United States, California, San Diego
Employees
11-50
Phone
+1 858-952-7652
Total raised
$28.5M
Founded date
1999
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Jun 17, 2020 | Funding round | $13.5M |
Mentions in press and media 39
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 8, 2024 | Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update | - Initial readout from first-line RAS-mut. mCRC randomized CRDF-004 trial expected in 2H 2024 - - Published preclinical data underscores the ability of onvansertib to overcome resistance to PARP inhibitors in high-grade serous ovarian carci... |
| Mar 6, 2024 | Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 | |
| Jan 19, 2022 | Cardiff Oncology : Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival - Form 8-K | Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival -12 of 35 (34%) patients treated per protocol at the recommende... |
| Dec 10, 2021 | Cardiff Oncology : Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium - Form 8-K | Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium SAN DIEGO, December 10, 2021 -- Cardiff Oncology... |
| Nov 18, 2021 | Cardiff Oncology : Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative - Form 8-K | Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative •Pfizer invests $15 million in Cardiff Oncology common shares •Adam Schayowitz, Ph.D., MBA, Vice President, Medicine Team... |
| Nov 18, 2021 | Cardiff Oncology Finds $15M From Pfizer | San Diego-based precision medicine company Cardiff Oncology said this morning that the publicly traded company has received a $15M equity investment from Pfizer. According to the company, the investment comes as part of the Pfizer Breakthro... |
| Nov 18, 2021 | Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative | SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need (i... |
| Nov 4, 2021 | Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates | SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need in... |
| Nov 4, 2021 | Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates - Form 8-K | Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates -Announced updated clinical data from lead KRAS-mutated metastatic colorectal cancer program showing an objective response rate and median progression free su... |
Show more
Reviews 0
FAQ about Cardiff Oncology
When was Cardiff Oncology founded?
Cardiff Oncology was founded in 1999.
How much funding has Cardiff Oncology raised?
Cardiff Oncology has raised $28.5M in total across 2 funding rounds.
What funding rounds has Cardiff Oncology raised?
Parsers VC lists 2 funding rounds of Cardiff Oncology, among them a funding round of $13.5M on Jun 17, 2020.
What has the press written about Cardiff Oncology?
Parsers VC has collected 39 articles mentioning Cardiff Oncology, among them “Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update” (Aug 8, 2024) and “Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024” (Mar 6, 2024).
Is Cardiff Oncology still active?
Yes, Cardiff Oncology is active; its latest activity on Parsers VC dates from Aug 27, 2024.